<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37988251</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms.</ArticleTitle><Pagination><StartPage>e29216</StartPage><MedlinePgn>e29216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29216</ELocationID><Abstract><AbstractText>The associations between longitudinal dynamics and the breadth of SARS-CoV-2 neutralizing antibody (nAb) response with various Long COVID phenotypes before vaccination are not known. The capacity of antibodies to cross-neutralize a variety of viral variants may be associated with ongoing pathology and persistent symptoms. We measured longitudinal neutralizing and cross-neutralizing antibody responses to pre- and post-SARS-CoV-2 Omicron variants in participants infected early in the COVID-19 pandemic, before widespread rollout of SARS-CoV-2 vaccines. Cross-sectional regression models adjusted for clinical covariates and longitudinal mixed-effects models were used to determine the impact of the breadth and rate of decay of neutralizing responses on the development of Long COVID symptoms, as well as Long COVID phenotypes. We identified several novel relationships between SARS-CoV-2 antibody neutralization and the presence of Long COVID symptoms. Specifically, we show that, although nAb responses to the original, infecting strain of SARS-CoV-2 were not associated with Long COVID in cross-sectional analyses, cross-neutralization ID<sub>50</sub> levels to the Omicron BA.5 variant approximately 4 months following acute infection was independently and significantly associated with greater odds of Long COVID and with persistent gastrointestinal and neurological symptoms. Longitudinal modeling demonstrated significant associations in the overall levels and rates of decay of neutralization capacity with Long COVID phenotypes. A higher proportion of participants had antibodies capable of neutralizing Omicron BA.5 compared with BA.1 or XBB.1.5 variants. Our findings suggest that relationships between various immune responses and Long COVID are likely complex but may involve the breadth of antibody neutralization responses.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-7193-0617</Identifier><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deitchman</LastName><ForeName>Amelia N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Saki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodansky</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Meghann C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerbleski</LastName><ForeName>Marian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maison</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveau</LastName><ForeName>Tyler-Marie</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardo</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wrin</LastName><ForeName>Terri</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petropoulos</LastName><ForeName>Christos J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenhouse</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AI174971</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI162249</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI144048</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI126521</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI146268</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2023 Mar 31:2023.03.30.23287923. doi: 10.1101/2023.03.30.23287923</RefSource><PMID Version="1">37034660</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19, SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 infection (PASC)</Keyword></KeywordList><CoiStatement><u>Conflicts of Interest:</u> MJP reports consulting fees for Gilead Sciences and AstraZeneca, outside the submitted work. TJH receives grant support from Merck and Co. and has consulted for Roche and Regeneron.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>21</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>21</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37988251</ArticleId><ArticleId IdType="mid">NIHMS1942195</ArticleId><ArticleId IdType="pmc">PMC10754238</ArticleId><ArticleId IdType="doi">10.1002/jmv.29216</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 2022; 377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Seessle J, Waterboer T, Hippchen T, et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis 2022; 74:1191&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Zhao H, Shannon CP, Tebbutt SJ. Omicron variants of SARS-CoV-2 and long COVID. Front Immunol 2022; 13:1061686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780375</ArticleId><ArticleId IdType="pubmed">36569883</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Kelly JD, Lu S, et al. Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infect Dis 2022; 9:ofab640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8588584</ArticleId><ArticleId IdType="pubmed">34780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol 2022; 43:268&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol 2022; 23:194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med 2022; 54:1473&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest 2023; 133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185:881&#x2013;95 e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens 2021; 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis 2023; 76:e487&#x2013;e90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) 2022; 3:371&#x2013;87 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG, Mustapic M, et al. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann Neurol 2022; 91:772&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjelltveit EB, Blomberg B, Kuwelker K, et al. Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clin Infect Dis 2023; 76:e60&#x2013;e70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384725</ArticleId><ArticleId IdType="pubmed">35959897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurahashi Y, Sutandhio S, Furukawa K, et al. Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections. Front Immunol 2022; 13:773652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8907139</ArticleId><ArticleId IdType="pubmed">35281007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K, Peluso MJ, Thomas R, et al. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Antibody-mediated neutralization of SARS-CoV-2. Immunity 2022; 55:925&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9118976</ArticleId><ArticleId IdType="pubmed">35623355</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 2021; 36:109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv 2021; 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324059</ArticleId><ArticleId IdType="pubmed">34330709</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Abellan J, Padilla S, Fernandez-Gonzalez M, et al. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. J Clin Immunol 2021; 41:1490&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman JD, Atyeo C, Zur Y, et al. Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19. medRxiv 2022.</Citation></Reference><Reference><Citation>Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat Commun 2022; 13:6478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9617541</ArticleId><ArticleId IdType="pubmed">36309490</ArticleId></ArticleIdList></Reference><Reference><Citation>Linderman SL, Lai L, Bocangel Gamarra EL, et al. Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection. J Clin Invest 2022; 132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711871</ArticleId><ArticleId IdType="pubmed">36256473</ArticleId></ArticleIdList></Reference><Reference><Citation>Odak I, Schultze-Florey CR, Hammerschmidt SI, et al. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Front Immunol 2022; 13:863039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8964088</ArticleId><ArticleId IdType="pubmed">35359969</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuh AJ, Satheshkumar PS, Dietz S, et al. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection. Microbiol Spectr 2022; 10:e0124722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9430572</ArticleId><ArticleId IdType="pubmed">35856710</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y, Huang Y, Benkeser D, et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat Commun 2023; 14:331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9851580</ArticleId><ArticleId IdType="pubmed">36658109</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Borisov O, Kee JJ, et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci Rep 2021; 11:23921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8671391</ArticleId><ArticleId IdType="pubmed">34907214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky A, Wang CY, Saxena A, et al. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight 2023; 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10393220</ArticleId><ArticleId IdType="pubmed">37288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez SE, Mann SA, Bodansky A, et al. Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq. Elife 2022; 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711525</ArticleId><ArticleId IdType="pubmed">36300623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med 2023; 29:344&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A, Tabernero J, Mukherjee U, et al. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry. Lancet Oncol 2023; 24:335&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9991062</ArticleId><ArticleId IdType="pubmed">36898391</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022; 399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi D, Hu J, Qian Z. A Lentiviral Pseudotype System to Characterize SARS-CoV-2 Glycoprotein. Methods Mol Biol 2023; 2610:187&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">36534292</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyseni I, Molesti E, Benincasa L, et al. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses 2020; 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551040</ArticleId><ArticleId IdType="pubmed">32927639</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KT, Han YJ, Wu GH, Huang KA, Huang PN. Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses 2022; 14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9322699</ArticleId><ArticleId IdType="pubmed">35891540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>